Alergia e Imunologia
Estudos: proteção da vacina diminui com o tempo em relação à infecção por COVID, mas a proteção contra hospitalização é duradoura.
19 Ago, 2021 | 12:27hStudies: COVID vaccine protection waning against infection but not hospitalization – CIDRAP
Comentário no Twitter (fio – clique para saber mais)
Very excited to share our most recent publication about #CovidVaccine effectiveness, just published today by the IVY network. Especially relevant in light of today’s news about #boosters (spoiler – I’m skeptical about the need for boosters for all). 🧵https://t.co/GbAxgzpo7R
— Nida Qadir, MD (@NidaQadirMD) August 18, 2021
Estudo laboratorial mostra que a vacinação heteróloga AstraZeneca/Pfizer produz uma forte resposta imune contra a variante delta do SARS-CoV-2.
18 Ago, 2021 | 13:06hConteúdos relacionados:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (vários artigos sobre o tema)
Comentário no Twitter (fio – clique para saber mais)
Mix and match vaccines, AZ then mRNA (@BioNTech_Group) achieves a very strong immune response against the Delta variant.
This is the 1st report to look at mix vs Delta, specifically.https://t.co/6N46cUh8HW @TheLancet pic.twitter.com/cvlHp2XtXJ— Eric Topol (@EricTopol) August 17, 2021
FDA autoriza aplicação de dose adicional da vacina contra Covid-19 em indivíduos imunocomprometidos – As demais pessoas, já plenamente vacinadas, não precisam de dose adicional neste momento.
16 Ago, 2021 | 12:10hComentários:
CDC, FDA recommend COVID booster for immune-compromised – CIDRAP
FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised – STAT
Covid booster: US approves third jab for the immunocompromised – BBC
CDC Panel Recommends 3rd Vaccine Dose For Immunocompromised People – NPR
6 Things To Know If You’re Immunocompromised And Considering A 3rd Shot – NPR
CDC recommends third Covid-19 vaccine dose for certain immunocompromised people – CNN
Comentário no Twitter
The Infectious Diseases Society of America (IDSA) supports the @FDA and @CDCgov's decision to authorize a supplemental vaccine dose for immunocompromised patients.
Read our statement: https://t.co/odzzSgIxnY pic.twitter.com/4PZfUwpjhM
— IDSA (@IDSAInfo) August 13, 2021
Estudo sugere um potencial benefício de proteção das vacinas MMR e DTP na redução do risco de infecções graves por Covid-19.
16 Ago, 2021 | 11:56h
Comentário no Twitter
New @MedCellPress
Prior Measles-Mumps-Rubella (MMR) or Tetanus-Diptheria-Pertussis (Tdap) vaccination induces a T-cell response that overlaps with #SARSCoV2 and appears to offer some (~20-30%) protection from severe Covid-19https://t.co/fYT7Qole8s pic.twitter.com/hMkHXvNQYU— Eric Topol (@EricTopol) August 14, 2021
Opinião | Hora de uma abordagem inteligente das doses de reforço.
13 Ago, 2021 | 12:20hTime for a Smart Approach to Boosters – Think Global Health
Estudo randomizado | Avaliação da vacina de mRNA da Moderna em adolescentes.
12 Ago, 2021 | 12:30hEvaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine
Conteúdos relacionados:
Comentários no Twitter
The mRNA-1273 vaccine was effective in preventing #COVID19 in 12-to-17-year-olds. Immune response was similar to young adults. https://t.co/aC3Dmjqe2T pic.twitter.com/9RxgHApW29
— NEJM (@NEJM) August 11, 2021
The @moderna_tx covid vaccine trial in 3,732 teens, placebo-controlled, published today @NEJM with both excellent safety profile and efficacy vs covid, and immune response as least as good as young adults https://t.co/PVmhjwgwsU pic.twitter.com/3uCmteaWNx
— Eric Topol (@EricTopol) August 11, 2021
Estudo randomizado | Terceira dose da vacina de mRNA da Moderna aumenta a imunidade em receptores de transplantes.
12 Ago, 2021 | 12:28hEditorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients
Conteúdos relacionados:
[Preprint] 3rd AstraZeneca shot gives strong immunity.
Comentários no Twitter
..1st randomized trial results of 3rd doses of Moderna vax for 120 people with organ transplants: month 4, their minimum anti-RBD antibody levels were 55% for 3rd dose vs 18% (still increasing a little in the placebo group). No cases of acute rejection https://t.co/BcfeyUEhx5 #IC
— Hilda Bastian, PhD (@hildabast) August 11, 2021
The authors conclude that a third-dose booster of mRNA-1273 vaccine should be considered for transplant recipients. https://t.co/Q3gakSaNjd pic.twitter.com/CMN8f7cq29
— NEJM (@NEJM) August 11, 2021
Características clínicas da trombocitopenia e da trombose imunes induzidas por vacina.
12 Ago, 2021 | 12:21hComentário: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD
Conteúdos relacionados:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)
Comentário no Twitter
The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce
— NEJM (@NEJM) August 11, 2021
Diretriz | Diagnóstico e tratamento do lúpus cutâneo – Terapia, fatores de risco e outros tópicos.
12 Ago, 2021 | 12:11hBreve revisão | Doenças bolhosas imunes.
12 Ago, 2021 | 11:54hImmunobullous disease – Clinical Medicine Journal